Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Moasser

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Cancer Research|June 22, 2022
Inactivating Amplified HER2: Challenges, Dilemmas, and Future DirectionsMark M Moasser
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Two dimensions in targeting HER2Mark M Moasser
Current Opinion in Investigational Drugs (London, England : 2000)|November 28, 2008
HER-2-directed, small-molecule antagonistsMichelle Arkin, Mark M Moasser
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 PositiveMarcia R Campbell, Mark M Moasser
JAMA Oncology|July 24, 2015
The Evolving Landscape of HER2 Targeting in Breast CancerMark M Moasser, Ian E Krop
Trends in Molecular Medicine|November 6, 2007
The HER family and cancer: emerging molecular mechanisms and therapeutic targetsNatalia V Sergina, Mark M Moasser
Cell Cycle (Georgetown, Tex.)|May 12, 2004
S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitorsOlga A Mizenina, Mark M Moasser
Seminars in Oncology|May 3, 2008
Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquiredA Jo Chien, Mark M Moasser
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Targeting HER2 by Combination TherapiesAna Ruiz-Saenz, Mark M Moasser
Chemistry & Biology|March 25, 2014
RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinasePeter Littlefield, Mark M Moasser, Natalia Jura
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Cancer Research|June 22, 2022
Inactivating Amplified HER2: Challenges, Dilemmas, and Future DirectionsMark M Moasser
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Two dimensions in targeting HER2Mark M Moasser
Current Opinion in Investigational Drugs (London, England : 2000)|November 28, 2008
HER-2-directed, small-molecule antagonistsMichelle Arkin, Mark M Moasser
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 PositiveMarcia R Campbell, Mark M Moasser
JAMA Oncology|July 24, 2015
The Evolving Landscape of HER2 Targeting in Breast CancerMark M Moasser, Ian E Krop
Trends in Molecular Medicine|November 6, 2007
The HER family and cancer: emerging molecular mechanisms and therapeutic targetsNatalia V Sergina, Mark M Moasser
Cell Cycle (Georgetown, Tex.)|May 12, 2004
S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitorsOlga A Mizenina, Mark M Moasser
Seminars in Oncology|May 3, 2008
Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquiredA Jo Chien, Mark M Moasser
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Targeting HER2 by Combination TherapiesAna Ruiz-Saenz, Mark M Moasser
Chemistry & Biology|March 25, 2014
RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinasePeter Littlefield, Mark M Moasser, Natalia Jura
Pageof 6